Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,766 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J; RETAIN Study Group. Prünte C, et al. Among authors: mahmood s. Br J Ophthalmol. 2016 Jun;100(6):787-95. doi: 10.1136/bjophthalmol-2015-307249. Epub 2015 Oct 9. Br J Ophthalmol. 2016. PMID: 26453639 Free PMC article. Clinical Trial.
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study.
Mitchell P, Sheidow TG, Farah ME, Mahmood S, Minnella AM, Eter N, Eldem B, Al-Dhibi H, Macfadden W, Parikh S, Dunger-Baldauf C, Mahgoub MM, Schmidt-Erfurth U; LUMINOUS study investigators. Mitchell P, et al. Among authors: mahmood s. PLoS One. 2020 Jun 3;15(6):e0233595. doi: 10.1371/journal.pone.0233595. eCollection 2020. PLoS One. 2020. PMID: 32492069 Free PMC article. Clinical Trial.
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.
Egan C, Zhu H, Lee A, Sim D, Mitry D, Bailey C, Johnston R, Chakravarthy U, Denniston A, Tufail A, Khan R, Mahmood S, Menon G, Akerele T, Downey L, McKibbin M, Varma A, Lobo A, Wilkinson E, Fitt A, Brand C, Tsaloumas M, Mandal K, Kumar V, Natha S, Crabb D; UK AMD and DR EMR Users Group. Egan C, et al. Among authors: mahmood s. Br J Ophthalmol. 2017 Jan;101(1):75-80. doi: 10.1136/bjophthalmol-2016-309313. Epub 2016 Dec 13. Br J Ophthalmol. 2017. PMID: 27965262
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema.
Denniston AK, Chakravarthy U, Zhu H, Lee AY, Crabb DP, Tufail A, Bailey C, Akerele T, Al-Husainy S, Brand C, Downey L, Fitt A, Khan R, Kumar V, Lobo A, Mahmood S, Mandal K, Mckibbin M, Menon G, Natha S, Ong JM, Tsaloumas MD, Varma A, Wilkinson E, Johnston RL, Egan CA; UK DR EMR Users Group. Denniston AK, et al. Among authors: mahmood s. Br J Ophthalmol. 2017 Dec;101(12):1673-1678. doi: 10.1136/bjophthalmol-2016-309838. Epub 2017 May 9. Br J Ophthalmol. 2017. PMID: 28487377 Free article.
Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser.
Gale R, Pikoula M, Lee AY, Denaxas S, Egan C, Tufail A, Taylor P; UK EMR Users Group. Gale R, et al. Br J Ophthalmol. 2021 Apr;105(4):549-554. doi: 10.1136/bjophthalmol-2020-315836. Epub 2020 Jun 12. Br J Ophthalmol. 2021. PMID: 32532760 Free PMC article.
First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.
Talks JS, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N, McKibbin M, Bailey C, Mahmood S; United Kingdom Aflibercept Users Group. Talks JS, et al. Among authors: mahmood s. Ophthalmology. 2016 Feb;123(2):337-343. doi: 10.1016/j.ophtha.2015.09.039. Epub 2015 Nov 12. Ophthalmology. 2016. PMID: 26578446 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Repeatability of visual function measures in age-related macular degeneration.
Aslam T, Mahmood S, Balaskas K, Patton N, Tanawade RG, Tan SZ, Roberts SA, Parkes J, Bishop PN. Aslam T, et al. Among authors: mahmood s. Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):201-6. doi: 10.1007/s00417-013-2421-5. Epub 2013 Jul 25. Graefes Arch Clin Exp Ophthalmol. 2014. PMID: 23884391 Clinical Trial.
1,766 results